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Abstract Despite advances in the roles of long non-coding
RNA (lncRNA) tumor suppressor candidate 7 (TUSC7) in
cancer biology, which has been identified as a tumor suppres-
sor by regulating cell proliferation, apoptosis, migration, in-
vasion, cell cycle, and tumor growth, the function of TUSC7
in hepatocellular carcinoma (HCC) remains unknown. In this
study, we observed that the expression of TUSC7 was im-
mensely decreased in HCC. Clinically, the lower expression
of TUSC7 predicted poorer survival and may be an indepen-
dent risk factor for HCC patients. Moreover, TUSC7 inhibited
cell metastasis, invasion, and epithelial-to-mesenchymal
transformation (EMT) through competitively binding miR-
10a. Furthermore, we found that TUSC7 could decrease the
expression of Eph tyrosine kinase receptor A4 (EphA4), a
downstream target of miR-10a as well as an EMT suppressor,
through TUSC7-miR-10a-EphA4 axis. Taken together, we
demonstrate that TUSC7 suppresses EMT through the
TUSC7-miR-10a-EphA4 axis, which may be a potential target
for therapeutic intervention in HCC.
Keywords TUSC7 . miR-10a . EphA4 . EMT . HCC





























1 Department of Hepatobiliary Surgery, First Affiliated Hospital of
Medical College of Xi’an Jiaotong University,
Xi’an 710061, Shaanxi, China
2 Department of Prosthodontics, State Key Laboratory of Military
Stomatology, School of Stomatology, The Fourth Military Medical
University, Xi’an, People’s Republic of China
3 Shaanxi Key Laboratory of Military Stomatology, Xi’an, Shaanxi,
People’s Republic of China
Tumor Biol. (2016) 37:11429–11441
DOI 10.1007/s13277-016-4892-6
Introduction
Hepatocellular carcinoma (HCC) is the most common type of
primary liver cancer and the second leading cause of death
from cancer worldwide [1]. Currently, the prognosis for
HCC patients remains poor, with a 5-year survival rate of
approximately 30 % after liver resection, which is considered
to be the best therapeutic strategy to treat HCC [2]. Local and
systemic metastases are the main reasons for the unsatisfacto-
ry prognosis of HCC patients [3]. Elucidating the underlying
molecular mechanisms for HCCmetastasis is critical for iden-
tifying novel therapeutic targets of HCC.
Epithelial-to-mesenchymal transformation (EMT) has been
widely accepted as a key mechanism underlying the metasta-
tic process of HCC [4]. During the development of EMT, the
expressions of epithelial markers such as E-cadherin, zonula
occludens-1, and claudins decrease while the expressions of
mesenchymal markers such as vimentin, N-cadherin, and fi-
bronectin increase [5]. The EMT process in HCC cells can be
regulated by various factors, including hypoxia [6], cytokines
[7], long non-coding RNAs (lncRNAs) [8], microRNAs [9],
and so on, and targeting the EMT process has been found to be
an attractive and promising strategy to prevent the metastasis
of HCC [7].
lncRNAs are RNA molecules over 200 nucleotides in
length with little protein-coding potential [10]. Previous stud-
ies have shown that aberrant lncRNA expression is observed
in human cancers, including those in the liver [11], breast [12],
colon [13], ovary [14], pancreas [15], and bladder [16].
lncRNAs have been identified with oncogenic properties
(KRASP, HULC, HOTAIR, MALAT1, HOTTIP, ANRIL, and
RICTOR) or oncosuppressive properties (MEG3, GAS5,
LincRNA-p21, PTENP1, TERRA, CCND1/CyclinD1, and
TUG1) or both (CCAT1 and XIST) [17, 18]. Tumor suppressor
candidate 7 (TUSC7), also called LOC285194 or LSAMP an-
tisense RNA3, is an lncRNA consisting of four exons of more
than 2 kb in length and is located at 3q13.31 [19]. Recent
studies indicated that lncRNA TUSC7 is downregulated in
cancers including gastric cancer [20], osteosarcoma [21], co-
lorectal cancer (CRC) [22], esophageal squamous cell carci-
noma (ESCC) [23], and so on. In gastric cancer, TUSC7 is a
p53-regulated tumor suppressor that acts in part by repressing
miR-23b to suppress tumor cell growth in vitro and in vivo
[20]. In osteosarcoma, depleting TUSC7 promoted prolifera-
tion of normal osteoblasts by regulating apoptotic and cell
cycle transcripts as well as the vascular endothelial growth
factor (VEGF) receptor 1 [21]. In human pancreatic ductal
adenocarcinoma (PDAC) and CRC, by analyzing the associ-
ation of TUSC7 expression with clinicopathologic features, it
was found that low TUSC7 expression was closely correlated
with lymph node metastasis, liver metastasis, and more distant
metastases [19, 22]. These data validated that TUSC7 is a
tumor suppressor by regulating cell proliferation, apoptosis,
migration, invasion, cell cycle, and tumor growth. However,
the exact role of TUSC7 in HCC progression and the under-
lying mechanisms remain unknown.
MicroRNAs (miRNAs) are an abundant group of endoge-
nous non-coding single-strand RNAs, and it is known that
aberrant miRNA expression profiles are causally connected
to tumor progression [24]. Recently, the competing endoge-
nous RNA (ceRNA) hypothesis proposed that a large number
of non-coding RNAs might function as molecular sponges for
miRNAs and, hence, functionally liberate other RNA tran-
scripts targeted by the aforementioned active miRNAs [25].
For example, lncRNA-UCA1 has been reported to play an
oncogenic role in breast cancer through directly interacting
with miR-143 to lower its expression and affect its down-
stream regulation [26]. miR-222 could be downregulated by
lncRNA-Gas5 in glioma, thereby suppressing the tumor ma-
lignancy [27, 28], and has been reported to play critical roles
in the development of a variety of human cancers [29–31],
including HCC [28, 32]. In HCC, acting as a tumor promoter,
the expression of miR-10a has been shown to be upregulated,
which accelerates the cell migration, invasion, and EMT [32,
33]. Additionally, Eph tyrosine kinase receptor A4 (EphA4), a
member of the Eph receptor tyrosine kinase family, has been
identified as an EMT suppressor in cancers [34–36]. It is re-
ported that miR-10a could regulate the EMT process in HCC
through directly binding the 3′-untranslated region (UTR) of
the EphA4 transcript [32]. However, limited knowledge is
available concerning whether TUSC7 could act as a sponge
for miR-10a to affect the biological processes of HCC and the
potential primary mechanism among TUSC7, miR-10a, and
EphA4 in HCC progression remains unknown.
In this study, we found that the expression of TUSC7 was
decreased in HCC and that TUSC7 may be a promising prog-
nostic or progression marker for HCC. Additionally, TUSC7
suppressed cell migration, invasion, and EMT of HCC cells.
Moreover, mechanistic analysis revealed that TUSC7 may
function as a ceRNA for miR-10a to regulate the expression
of EphA4 to suppress EMT in HCC, thus playing an
oncosuppressive role in HCC pathogenesis. Here, we provide
the first evidence for the TUSC7-miR-10a-EphA4 axis, shed-
ding new light on the mechanism of HCC.
Materials and methods
Clinical samples
HCC samples were collected from 75 patients including 51
males and 24 females, who underwent resection of their pri-
mary HCC in the Department of Hepatobiliary Surgery at the
First Affiliated Hospital of Xi’an Jiaotong University during
January 2009 to December 2011. Patients did not receive any
preoperative chemotherapy or embolization.
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Patients’ demographic and clinicopathologic data were ob-
tained through a review of hospital records. And disease re-
currence and survival information was updated at each follow-
up visit. The time between the surgery date and first disease
recurrence date was calculated as disease-free survival (DFS).
The time between the diagnostic biopsy and surgery date to
death or last follow-up was determined as overall survival
(OS) duration.
Cell culture
The human immortalized normal hepatocyte cell line (LO2)
and six HCC cell lines (HepG2, MHCC97L, Hep3B, SMMC-
7721, MHCC97H, and Huh7) were obtained from the
Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences, Shanghai, China. All cells were cul-
tured in complete Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Grand Island, NY, USA) containing 10 %
fetal bovine serum (FBS; Gibco) with 100 units/mL penicillin
and 100 μg/mL streptomycin (Sigma, St. Louis, MO, USA) in
a humidified incubator containing 5 % CO2 at 37 °C.
Cell transfection
Three TUSC7-specific small interfering RNAs (siRNAs), the
TUSC7-siControl (Table 1), pcDNA3.1-TUSC7 (pcDNA/
TUSC7), and pcDNA3.1-Control (pcDNA/Control), were
purchased from Invitrogen (Carlsbad, CA, USA). Four
miRNA vectors, including anti-miR-10a, anti-Control, miR-
10a, and miR-10a-Control , were purchased from
GeneCopoeia (Guangzhou, China). All cell transfections were
performed according to the manufacturer’s protocol.
Luciferase reporter assay
To search for the miR-10a binding site of TUSC7, we used a
number of bioinformatics tools (MicroRNA,Mircode, Starbase
v2.0, and RNAhybrid). The putative miR-10a target binding
sequence in TUSC7 and its binding site mutant were synthe-
sized and cloned downstream of the luciferase gene in the
pmirGLO luciferase vector (Promega, Madison, WI, USA).
Hep3B cells were co-transfected with wild-type or mutated
pmirGLO-miR-10a reporter plasmid and pcDNA/Control or
pcDNA/TUSC7 using Lipofectamine 2000 (Invitrogen). After
48 h, the cells were harvested and luciferase activity was mea-
sured using the dual-luciferase reporter assay system (Promega,
Madison, WI, USA). Firefly luciferase activity was normalized
to the Renilla luciferase activity. Results were obtained from
three independent experiments performed in triplicate.
RNA extraction and quantitative real-time PCR
Total RNAwas extracted from HCC tissues and cell lines using
TRIzol (Invitrogen) following the manufacturer’s instructions.
The RNA levels of TUSC7 and EphA4 were determined by
quantitative real-time PCR (qRT-PCR) and calculated using the
2−ΔΔCt method, with the Ct values normalized usingGAPDH as
an internal control. The primers are listed in Table 2. miRNAs
were obtained using the mirVana MiRNA Isolation Kit
(Ambion, Austin, TX, USA). Mature miR-10a and U6 snRNA
were reversely transcribed using Stem-loop RT Primer with
miScript II RT Kit (Qiagen, Valencia, CA, USA). qRT-PCR
was performed using SYBR Green PCR Master Mix (Qiagen)
in an ABI 7500 system (Applied Biosystems, USA).
Western blot
Western blot analysis was performed using standard tech-
niques. The following antibodies were used: E-cadherin
(3195S, Cell Signaling, Beverly, MA, USA), vimentin (sc-
6260, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
EphA4 (SRP00347b, Saierbio, Tianjin, China), and β-actin
(sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA, USA).










TUSC7-siControl Sense: 5′- UUCUCCGAACGUGUCACGUTT-3′
Antisense: 5′-ACGUGACACGUUCGGAGAATT-3′
Table 2 Primers used in qRT-PCR
Primer name Sequence (5′–3′)
GAPDH Forward: 5′-CCGGGAAACTGTGGCGTGATGG-3′
Reverse: 5′-AGGTGGAGGAGTGGGTGTCGCTGTT-3′
TUSC7 Forward: 5′- CACTGCCTATGTGCACGACT-3′
Reverse: 5′- AGAGTCCGGCAAGAAGAACA-3′
E-cadherin Forward: 5′- GCCGCTGGCGTCTGTAGGAA -3′
Reverse: 5′- TGACCACCGCTCTCCTCCGA -3′
Vimentin Forward: 5′-GAGAACTTTGCCGTTGAAGC-3′
Reverse: 5′-GCTTCCTGTAGGTGGCAATC-3′
EphA4 Forward: 5′ - ATGGATCCTGTTGCCCTCAC -3′
Reverse: 5′- CAGAATTCCTCCTACCCTTACC -3′
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Wound healing assays
To determine cell motility, HCC cells were seeded into six-
well plates and grown to 80–90 % confluence. A 200-μL
sterile plastic tip was used to create a wound line across the
surface of plates, and cellular debris was removed by washing
with phosphate-buffered saline (PBS). Cells were cultured in
DMEM in a humidified incubator with 5 % CO2 at 37 °C for
48 h, and then images were taken with a phase-contrast
microscope.
Transwell assays
The 8 μM pore-size transwell inserts (Nalge Nunc, Penfield,
New York, NY, USA) were coated with Matrigel (BD
Biosciences, Franklin Lakes, NJ, USA) at 1:8 dilution on the
inner layer. Hep3B and MHCC97H cells were resuspended
with reduced serum DMEM, and the density was adjusted to
2.5×105/mL 48 h after transfection. A 200-μL cell suspen-
sion was added into the upper chamber, and 750 μL DMEM
containing 10 % FBS was added into the lower chamber and
then incubated for 24 h.
Cells were fixed in 4 % paraformaldehyde for 2 min
and then permeabilized in 100 % methanol for 20 min.
The cells on the inner layer were softly removed with a
cotton swab, and the adherent cells on the undersurface
of the insert were stained with 0.3 % crystal violet dye
for 15 min. The filters were washed with PBS, and
images were taken. Cells on undersurface were counted
under a light microscope.
Immunohistochemistry
Immunohistochemistry staining was performed on
paraformaldehyde-fixed paraffin sections. The sections
were dewaxed and dehydrated. Following rehydration
and antigen retrieval in citrate buffer, endogenous per-
oxidase activity was blocked for 10 min using 3.0 %
hydrogen peroxide. The sections were blocked for
30 min using 10 % goat plasma and then separately
incubated with the primary antibodies directed against
E-cadherin (1:400) and vimentin (1:200) at 4 °C over-
night. The primary antibody was detected using bio-
t inylated secondary ant ibodies (Golden Bridge
Biotechnology, Zhongshan, China) according to the
manufacturer’s recommendations. The sections were vi-
sualized with diaminobenzidine and counterstained with
hematoxylin and then dehydrated in alcohol and xylene
and mounted onto glass slides.
Statistical analysis
Results are presented as mean ±SD. The SPSS statistical
package for Windows version 13 (SPSS, Chicago, IL, USA)
and GraphPad Prism 5 software (GraphPad Software, Inc.,
San Diego, CA, USA) were used for the Pearson chi-square
Fig. 1 The expression levels of
TUSC7 in HCC. Comparing
differences in the expression
levels of TUSC7 between a HCC
and matched non-tumor tissues, b
aggressive and non-aggressive
tumor tissues, c HCC tissues
arising from recurrent and non-
recurrent groups, and d HCC cell
lines and the immortalized hepatic
cell line LO2. Values are depicted
as mean ± SD; *p< 0.05, by t test
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test, a two-tailed Student’s t test, a Kaplan-Meier plot, a log-
rank test, or an ANOVAwhere appropriate. Differences were
considered to be significant when p<0.05.
Results
The expression of TUSC7 was decreased in HCC
First, we examined the lncRNA TUSC7 expression level
in 75 paired HCC tissues and adjacent non-tumor tis-
sues by qRT-PCR and normalized them to GAPDH. Our
results showed that TUSC7 levels were significantly de-
creased in HCC tissues compared with adjacent non-
tumor tissues (p < 0.05, Fig. 1a). HCC cases with at
least one of the clinicopathological features, including
intrahepatic spreading, venous infiltration, or tumor in-
vasion, tend to be considered as aggressive HCC tis-
sues. When compared with non-aggressive HCC tissues,
TUSC7 levels were markedly downregulated in aggres-
sive HCC tissues (p < 0.001, Fig. 1b). Furthermore,
TUSC7 levels were notably lower in tumor tissues aris-
ing from patients with tumor recurrence than that with-
out tumor recurrence (p< 0.001, Fig. 1c). Then, expres-
sion levels of TUSC7 in HCC cells were determined by
qRT-PCR. Our experiments showed that TUSC7 expres-
sion was significantly downregulated in all HCC cell
lines when compared with that in LO2 cells (p< 0.05,
Fig. 1d). These data suggest that TUSC7 was frequently
downregulated in HCC, especially in those patients with
metastases and recurrence, suggesting that TUSC7 might
be associated with migration and metastasis of HCC
cells.
Clinical significance of TUSC7 expression in HCC
To determine whether TUSC7 expression is associated
with clinicopathological features in HCC patients, HCC
patients were divided into two different groups accord-
ing to the median level of TUSC7 expression. Further
analysis showed that the expression level of TUSC7 was
significantly correlated with tumor nodes (p< 0.001), ve-
nous infiltration (p= 0.017), Edmondson-Steiner grading
(p = 0.003), and tumor-node-metastasis (TNM) tumor
stage (p= 0.004) (Table 3). Thus, our results demonstrat-
ed that the reduced expression of TUSC7 was correlated
with poor prognostic features of HCC.
Kaplan-Meier survival curves further revealed that
patients with lower TUSC7 expression had a significant-
ly reduced OS and DFS than those with high TUSC7
expression (p< 0.05, respectively, Fig. 2a, b). Moreover,
multivariate Cox proportional hazard regression analysis
indicated that venous infiltration and TUSC7 expression
were independent prognostic factors for predicting both
3-year OS and DFS in HCC patients (p = 0.007 and
0.015, respectively, Table 4). The data implied that
TUSC7 may be a promising prognostic or progression
marker for HCC.
TUSC7 inhibits the migration and invasion of HCC cells
To explore the biological significance of TUSC7 in
HCC progression, we manipulated TUSC7 levels in
HCC cells and examined the alteration of the metastatic
behavior of HCC cells. Firstly, we used TUSC7-siRNAs
(TUSC7-siRNA1, TUSC7-siRNA2, and TUSC7-siRNA3)
to downregulate the expression of TUSC7 in Hep3B
cells. Additionally, pcDNA/TUSC7 vector and pcDNA/
Table 3 Correlation between the clinicopathologic characteristics and
expression of TUSC7 in HCC
Characteristics Total no. of
patients (n= 75)
No. of patients p
TUSC7high TUSC7low
Age (year)
<50 19 8 11 0.362
≥50 56 29 27
Gender
Male 51 27 24 0.466
Female 24 10 14
HBV
Absent 55 26 29 0.346
Present 20 11 19
Serum AFP level (ng/mL)
<400 18 7 11 0.309
≥400 57 30 27
Tumor size (cm)
<5 43 22 21 0.366
≥5 32 13 19
No. of tumor nodes
1 40 28 12 <0.001***
≥2 35 9 26
Cirrhosis
Absent 55 28 27 0.651
Present 20 9 11
Venous infiltration
Absent 54 22 32 0.017*
Present 21 15 6
Edmondson-Steiner grading
I + II 49 18 31 0.003**
III + IV 26 19 7
TNM tumor stage
I + II 43 15 28 0.004**
III + IV 32 22 10
HBV hepatitis B virus, AFP alpha-fetoprotein, TNM tumor-node-
metastasis
*p< 0.05; **p < 0.01; ***p < 0.001
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Control vector were transfected into MHCC97H cells.
The result of qRT-PCR revealed that TUSC7-siRNA3
was the most effective siRNA which inhibited the ex-
pression of TUSC7 in Hep3B cells significantly
(p< 0.05, Fig. 3a). Then, we found that downregulation
of TUSC7 resulted in increased migration and invasion
of Hep3B cells (Figs. 3b and 4a). Conversely, the
pcDNA/TUSC7 vector significantly upregulated the
levels of TUSC7 in MHCC97H cells (p< 0.05, Fig. 3a)
and resulted in diminished migration and invasion of
MHCC97H cells (Figs. 3c and 4b). These data indicated
that TUSC7 can inhibit migration and invasion of HCC
cells.
TUSC7 suppresses EMT in HCC
It is well recognized that EMT plays a critical role in HCC cell
migration and invasion [37]. Therefore, we explored whether
TUSC7 had effects on EMT of HCC. Firstly, we respectively
analyzed the correlation of expression levels of TUSC7 and E-
cadherin as well as TUSC7 and vimentin in 75 paired HCC
tissues and adjacent non-tumor tissues by immunohistochem-
ical staining. We found that E-cadherin expression was
distinctly repressed and vimentin expression was notably in-
creased in the low TUSC7 tissues group compared to that in
the high group (Fig. 5(a–d)). Moreover, the results were con-
firmed by qRT-PCR in HCC tissues (Fig. 5(e, f)) and western
blot in HCC cells (Fig. 5(g)). Therefore, we conclude that
TUSC7 inhibited EMT in HCC.
miR-10a is a downstream target of TUSC7
As we have mentioned before, recent studies show that
TUSC7 may function as a competing endogenous RNA
(ceRNA) or a molecular sponge by modulating the biological
functions and concentration of miRNAs in cancers [20, 38].
To investigate the potential downstream miRNAs of TUSC7
and their interactions in HCC, bioinformatics tools
(MicroRNA, Mircode, Starbase v2.0, and RNAhybrid) were
used to analyze the potential complementary base pairing be-
tween TUSC7 and miRNAs. The result revealed that dozens
of miRNA binding sites were present in TUSC7 (data not
shown).We found that miR-10a contained the complementary
sequence of TUSC7 (Fig. 6a). Additionally, our results have
shown that TUSC7 could repress EMT progression of HCC
(Fig. 5(a–g)) and miR-10a has been reported to facilitate EMT
Table 4 Multivariate Cox
regression analysis of 3-year
overall and disease-free survival
of 75 HCC patients
Variables Overall survival Disease-free survival
HR 95 % CI p HR 95 % CI p
No. of tumor nodules 0.801 0.347, 1.853 0.605 0.598 0.256, 1.400 0.236
Venous infiltration 0.259 0.101, 0.665 0.005** 0.303 0.121, 0.759 0.011*
TNM tumor stage 1.105 0.278, 4.399 0.887 1.089 0.280, 4.230 0.902
TUSC7 expression 3.411 1.392, 8.357 0.007** 2.928 1.227, 6.985 0.015*
Edmondson-Steiner grading 1.905 0.837, 4.338 0.125 1.660 0.727, 3.792 0.229
HR hazard ratio, CI confidence interval
*p< 0.05; **p < 0.01
Fig. 2 Prognostic significance of TUSC7 in HCC cases. Kaplan-Meier 3-
year a overall and b disease-free survival curves of HCC patients
according to the level of TUSC7 expression. The low TUSC7 group
(≤0.33, n = 53); the high TUSC7 group (>0.33, n = 22). The mean
expression value (0.33) obtained for TUSC7 of the 75 HCC samples
detected by qRT-PCR was chosen as the cutoff value. *p < 0.05, by log-
rank test
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in HCC [32]; we then focused on miR-10a. To further inves-
tigate whether miR-10a was a functional target of TUSC7, the
dual-luciferase reporter assay was performed. We found that
co-transfection of pcDNA/TUSC7 and miR-10a-WT strongly
decreased the luciferase activity while co-transfection of
pcDNA/Control and miR-10a-WT did not change the lucifer-
ase activity (Fig. 6b), suggesting that miR-10a was a target of
TUSC7. In parallel, we constructed a reporter plasmid where
the TUSC7 seed region binding site was mutated (miR-10a-
Mut) to test binding specificity (Fig. 6a). Consequently, co-
transfection of pcDNA/TUSC7 and miR-10a-Mut did not
change luciferase activity (Fig. 6b). Thus, these results dem-
onstrated that TUSC7 could directly bind to miR-10a at the
miRNA recognition site.
To further confirm whether TUSC7 exerted its function
through miR-10a, we determined the expression levels of
miR-10a in Hep3B cells transfected with TUSC7-siRNA3
and in MHCC97H cells transfected with pcDNA/TUSC7.
The qRT-PCR results revealed that miR-10a expression was
visibly elevated in Hep3B cells transfected with TUSC7-
Fig. 3 Wound healing assays to
assess the effect of TUSC7 on cell
mobility. a qRT-PCR analysis
revealed that TUSC7 expression
in Hep3B cells was reduced most
obviously by TUSC7-siRNA3
and pcDNA/TUSC7 largely
increased the TUSC7 expression
in MHCC97H cells. bWound
healing assays to assess the effect
of TUSC7 on cell mobility in
Hep3B cells. cWound healing
assays to assess the effect of
TUSC7 on cell mobility in
MHCC97H cells.*P< 0.05, by t
test
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siRNA3 and clearly reduced in MHCC97H cells transfected
with pcDNA/TUSC7 (Fig. 6c, d, respectively). It has been
reported that miR-10a could promote EMT in HCC through
the miR-10a/EphA4 axis [32]. Our data showed that ectopic
expression of TUSC7 could affect the messenger RNA
(mRNA) levels of EphA4 in HCC cells (Fig. 6e, f), which
further confirmed that miR-10a is a target of TUSC7 in
HCC. Taken together, these data suggest that TUSC7 might
repress EMT through the TUSC7-miR-10a-EphA4 axis in
HCC.
miR-10a reverses the inhibitory effects of TUSC7 in HCC
cells
Although our experiments had confirmed that miR-10a was a
target of TUSC7, the function of miR-10a in TUSC7-induced
inhibition in HCC cells remained unclear. And in order to con-
firm whether TUSC7 could suppress EMT through the TUSC7-
miR-10a-EphA4 axis, the further experiments were performed.
Wound healing assays (Fig. 7a–d) and Transwell assays (Fig. 7f–
i) showed that miR-10a could largely reverse the inhibitory effect
ofTUSC7 onHCCcellmigration and invasion.Western blot also
revealed that the inhibition of EphA4 protein expression and
EMT by TUSC7 could be largely reversed by miR-10a
(Fig. 7e). These results indicated that miR-10a could reverse
the inhibitory effects of TUSC7 in HCC cells and TUSC7 could
suppress EMT through the TUSC7-miR-10a-EphA4 axis.
Discussion
HCC patients currently have a poor prognosis, and it is with-
out doubt that early detection and treatment could
Fig. 4 Transwell assays to assess the effect of TUSC7 on migration and invasion in HCC cells. a The effect of TUSC7 on migration and invasion ability
in Hep3B cells. b The effect of TUSC7 on migration and invasion ability in MHCC97H cells. *P< 0.05, by t test
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significantly increase their chances of survival. Recently,
lncRNAs have shown great therapeutic potential for human
diseases, including HCC [39]. For example, studies from
Yuan SX et al. have revealed that DANCR increases stemness
and offers a potential prognostic marker, and a therapeutic
target, for HCC [40]. Research from Chen CL et al. unveiled
the molecular mechanisms of how PTENP1 repressed the tu-
morigenic properties of HCC cells and demonstrated the po-
tential of the SB-BV hybrid vector for PTENP1 lncRNAmod-
ulation and HCC therapy [41]. Accordingly, TUSC7was iden-
tified as a robust suppressor of cancer [21]. In this study, we
found that TUSC7 expression inHCCwas significantly down-
regulated. TUSC7 expression in HCC tissues was negatively
associated with more tumor nodes, more venous infiltration,
advanced Edmondson-Steiner grading, and advanced TNM
tumor stage. Moreover, comparison of Kaplan-Meier survival
curves indicated that patients with lower TUSC7 expression in
HCC tissues had notably worse prognosis. TUSC7 was also
confirmed to be an independent risk factor for HCC patients.
Altogether, these clinical data suggest strongly that TUSC7 is
critical for prognosis determination in HCC patients.
Furthermore, we tested the action of TUSC7 on tumor inva-
sion and metastasis of HCC cells by taking different ap-
proaches and found that TUSC7 inhibited cell invasion and
metastasis in HCC.
EMT, a dynamic and reversible cellular process, is charac-
terized by a loss of cell polarity and intracellular junctions and
acquirement of mesenchymal features, which could result in
Fig. 5 TUSC7 inhibi ted EMT progress ion in HCC. a–d
Immunohistochemistry staining of E-cadherin and vimentin in HCC tis-
sues. In cases of high TUSC7 expression tissue group (a, b), there was
strong E-cadherin and no detectable vimentin protein expression in the
same tissue section. In contrast, in the cases of low TUSC7 expression
tissue group (c, d), there was no detectable E-cadherin and strong
vimentin protein expression. Values are depicted as mean ± SD;
**p < 0.001, by t test. Scale bar = 100 μm. e, f Expression of EMT
mRNAmarkers was assessed by qRT-PCR in the low TUSC7 expression
tissue group (≤0.33, n = 38) and high TUSC7 expression tissues group
(>0.33, n = 37), both groups from HCC samples. g Hep3B and
MHCC97H cells with different TUSC7 levels were subjected to western
blot for E-cadherin and vimentin. Representative western blot showed
that downregulation of TUSC7 obviously increased protein expression
of vimentin and reduced E-cadherin expression in HCC cells.
*P< 0.05, by t test
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increased HCC cell migration and invasion [42]. Recent stud-
ies showed that lncRNAs may play critical roles in the EMT
progress not only in HCC but also in other cancers [43–45].
Furthermore, it has been found that some lncRNAs could
promote EMT [45, 46] while some could restrain EMT [47,
48]. For example, lncRNA-AOC4P has been shown to act as
an HCC tumor suppressor by enhancing vimentin degradation
and suppressing EMT progress [47]. Overexpression of
lncRNA-UCA1 induced EMT and increased the migratory
and invasive abilities of bladder cancer cells [49]. lncRNA-
ATB may also act on colon tumorigenesis by suppressing E-
cadherin expression and promoting EMT [50]. In this study,
we analyzed EMT biomarkers of HCC tissues by using im-
munohistochemistry and qRT-PCR and those of HCC cells by
western blot. Then, we determined the expression of an epi-
thelial marker (E-cadherin) and mesenchymal marker
(vimentin) in HCCwith either low or high TUSC7 expression.
Interestingly, it was found that TUSC7 expression was posi-
tively associated with E-cadherin expression and negatively
associated with vimentin expression in HCC. We concluded
that TUSC7 could suppress EMT in HCC.
Growing evidence suggests that lncRNA may act as a
ceRNA to regulate miRNAs in cancer progression [51]. As
we have stated before, TUSC7 acts as a tumor suppressor in
human cancers by interacting with miRNAs, such as miR-23b
[20] and miR-211 [38]. It has been reported that miR-10a
could facilitate cell migration, invasion, and EMT by directly
targeting the 3′-UTR of EphA4 transcript to reduce its expres-
sion in HCC [32]. EphA4 could inhibit cell migration and
invasion by regulating the EMT process through the β1-
integrin signaling pathway [32]. Hence, combining our previ-
ous results and the bioinformatics analysis, we focused on
miR-10a and its downstream target EphA4. Our results
showed that miR-10a was indeed a downstream target of
TUSC7. We found that acting as a sponge of miR-10a,
Fig. 6 TUSC7 targets miR-10a. a
TUSC7 binding sequence in miR-
10a-WT and sequence of miR-
10a-Mut. b TUSC7 overexpres-
sion significantly suppressed the
luciferase activity that carried
wild-type but not mutant-type
miR-10a. And TUSC7
overexpression almost had no
effect on the luciferase activity
that carried neither wild-type nor
mutant-type miR-10a. n= three
repeats with similar results;
**p< 0.01, by t test. c, d qRT-
PCR revealed that TUSC7 could
negatively regulate miR-10a
expression; e, f qRT-PCR
revealed that TUSC7 could
positively regulate the mRNA
expression level of EphA4.
*P< 0.05, by t test
Fig. 7 miR-10a reverses the inhibitory effects of TUSC7 on HCC cells.
a–d Wound healing assays showed that miR-10a largely reversed the
inhibitory effect of TUSC7 on cell mobility. eWestern blot revealed that
miR-10a largely reversed the inhibitory effect of TUSC7 on EMT. f–i
Transwell assays showed that miR-10a could largely reverse the inhibi-
tory effect of TUSC7 on cell migration and invasion.* P <0.05,
**P<0.01, ***P<0.001, by t test
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TUSC7 could therefore directly interact with miR-10a to re-
strain its function. Thus, when the expression level of TUSC7
was reduced, its inhibition on miR-10a would be attenuated.
The expression level of miR-10a would then be increased,
which could lead to decreased expression of EphA4.
Therefore, we have confirmed that the downregulation of
TUSC7 could enhance miR-10a expression to reduce EphA4
expression, thereby promoting migration, invasion, and EMT
in HCC, at least in part.
In summary, our data indicate that TUSC7may function as
a tumor suppressor in HCC. Mechanistically, our experimen-
tal data demonstrate that targeting the TUSC7-miR-10a-
EphA4 axis may represent a novel therapeutic application in
HCC.
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